Dae Kee Kim Professor Emeritus
Dae-Kee Kim is a professor at the department of pharmacy, college of pharmacy and is a prominent professor in the field of new drug development. He received his ph.D. in medicinal chemistry at the State University of New York at Buffalo, USA, and he is currently doing his research to develop new anticancer and antifibrotic drugs. He successfully commercialized the 1st new drug in Korea, an anticancer platinum complex 'Sunpla' in 1999 and the 13th new drug in Korea, an anti-erectile dysfuntion drug 'Mbix' in 2007. He developed 'Vactosertib (EW-7197)' as a potential anticancer/antifibrotic agent, and nine 1b/2a clinical trials are currently oning in USA and Korea. He has published 120 articles in SCI journals.
Research Record
- EW-7197, transforming growth factor β inhibitor, combined with irreversible electroporation for improving skin wound in a rat excisional model Scientific Reports, 2024, v.14 no.1, 12779
- Beneficial Effects of a Curcumin Derivative and Transforming Growth Factor-β Receptor I Inhibitor Combination on Nonalcoholic Steatohepatitis DIABETES & METABOLISM JOURNAL, 2023, v.47 no.4, 500-513
- Different routes of administering EW-7197 versus EW-7197?HBr for preventing peritoneal adhesion in a rat model SURGERY, 2023, v.173 no.4, 1008-1014
- Discovery of (E)-3-(3-((2-Cyano-4' -dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic Acid Methyl Ester, an Intestine-Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis JOURNAL OF MEDICINAL CHEMISTRY, 2022, v.65 no.14, 9974-10000
- EW-7197 Attenuates the Progression of Diabetic Nephropathy in db/db Mice through Suppression of Fibrogenesis and Inflammation Endocrinology and Metabolism, 2022, v.37 no.1, 96-111
- Synthesis, biological evaluation and molecular modelling of 2,4-disubstituted-5-(6-alkylpyridin-2-yl)-1H-imidazoles as ALK5 inhibitors JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2020, v.35 no.1, 702-712
- Vactosertib, a Novel, Orally Bioavailable Activin Receptor-Like Kinase 5 Inhibitor, Promotes Regression of Fibrotic Plaques in a Rat Model of Peyronie's Disease WORLD JOURNAL OF MENS HEALTH, 2020, v.38 no.4, 552-563
- EW-7197 eluting nano-fiber covered self-expandable metallic stent to prevent granulation tissue formation in a canine urethral model PLoS ONE, 2018, v.13 no.2, e0192430
- EW-7197, an oral transforming growth factor beta type I receptor kinase inhibitor, for preventing peritoneal adhesion formation in a rat model SURGERY, 2018, v.164 no.5, 1100-1108
- Cancer upregulated gene 2 induces epithelial-mesenchymal transition of human lung cancer cells via TGF-β signaling Oncotarget, 2017, v.8 no.3, 5092-5110
- EW-7197, an activin-like kinase 5 inhibitor, suppresses granulation tissue after stent placement in rat esophagus GASTROINTESTINAL ENDOSCOPY, 2017, v.86 no.1, 219-228
- Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells Cancer Science, 2016, 26 JAN 2016
- TGF-β Type I Receptor Kinase Inhibitor EW-7197 Suppresses Cholestatic Liver Fibrosis by Inhibiting HIF1α-Induced Epithelial Mesenchymal Transition Cellular Physiology and Biochemistry, 2016, v.38 no.2, 571-588
- Antitubercular activities of the novel synthesized 1,2,4-triazole derivatives Bulletin of the Korean Chemical Society, 2015, v.36 no.1, 43-51
- Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells Oncotarget, 2015, v.6 no.35, 37526-37543
- EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling Cellular and molecular life sciences : CMLS, 2015, v.72 no.10, 2023-2039
-
Phosphorylation status determines the opposing functions of Smad2/Smad3 as STAT3 cofactors in T
H 17 differentiation Nature Communications, 2015, v.6 - Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-β type i receptor kinase Bioorganic and Medicinal Chemistry Letters, 2015, v.25 no.22, 5228-5231
- 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-beta type I receptor kinase BIOORGANIC & MEDICINAL CHEMISTRY, 2014, v.22 no.9, 2724-2732
- An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition Cancer Letters, 2014, v.351 no.1, 72-80
- Discovery of N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197) : A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF-beta Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent JOURNAL OF MEDICINAL CHEMISTRY, 2014, v.57 no.10, 4213-4238
- EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis Molecular Cancer Therapeutics, 2014, v.13 no.7, 1704-1716
- [학술지논문] Synthesis, biological evaluation and molecular modelling of 2,4-disubstituted-5-(6-alkylpyridin-2-yl)-1H-imidazoles as ALK5 inhibitors JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2020, v.35 no.1 , 702-712
Academic Background
State University of New York at Buffalo Ph.D.(Medicinal Chemistry)
Seoul Nat'l Univ. 약학석사(약학과)
Seoul Nat'l Univ. 약학사(약학과)
Work Experience
인투젠 대표이사 2000-07-13 ~ 2002-08-31
SK 케미칼 대우이사/상무보/상무대우 1997-01-01 ~ 2001-02-10
선경인더스트리 선임연구원/책임연구원 1989-01-21 ~ 1996-12-31
한국화학연구소 선임연구원 1987-09-22 ~ 1988-12-04
ICN-Nucleic Acid Research Institute (Postdoc) 1986-10-01 ~ 1987-09-30